Skip to main content

Table 1 Liver function tests for the groups treated with or without CCl4 or MSC-Smad7 for 21 days

From: Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis

Group

Number

ALT(U/L)

AST(U/L)

ALB (g/dl)

TP (g/dl)

Control

6

26.8 ± 9.2

66.9 ± 7.8

43.7 ± 9.1

70.7 ± 7.4

CCl4-treated

6

128.6 ± 10.3***

138.4 + 6.1***

23.4 ± 8.6**

43.8 + 6.4***

CCl4+MSC

6

119.6 ± 10.1***

135.7 ± 6.8***

22.8 ± 8.1**

44.9 ± 6.3***

CCl4+MSC-Smad7

6

65.3 ± 11.9*, ###

82.9 ± 7.7**,###

31.7 ± 7.1*

63.6 ± 5.3###

  1. ALT alanine transaminase, AST aspartate transaminase, ALB albumin, TP total protein. *P < 0.05, **P < 0.01 and ***P < 0.001 comparing with the control group. #P < 0.05, ##P < 0.01 and ###P < 0.001 comparing with the CCl4-treated group